Sökning: WFRF:(Jenmalm Maria C) >
The effect of tinza...
-
Karlsson, AnnaDepartment of Obstetrics and Gynecology, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden
(författare)
The effect of tinzaparin on biomarkers in FIGO stages III-IV ovarian cancer patients undergoing neoadjuvant chemotherapy - the TABANETOC trial : study protocol for a randomized clinical multicenter trial
- Artikel/kapitelEngelska2024
Förlag, utgivningsår, omfång ...
-
Medical Journals Sweden,2024
-
electronicrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:umu-228114
-
https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-228114URI
-
https://doi.org/10.2340/1651-226X.2024.40207DOI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Background: Tinzaparin, a low-molecular weight heparin (LMWH), has shown anti-neoplastic properties in animal models and in in vitro studies of human cancer cell lines. The reduction of CA-125 levels during neoadjuvant chemotherapy (NACT) in patients with epithelial ovarian cancer (EOC) co-varies with the prognosis; the larger the decrease in CA-125, the better the prognosis.Purpose: This study aims to evaluate the potential anti-neoplastic effects of tinzaparin by investigating changes in serum CA-125 levels in advanced EOC patients who receive NACT.Material and methods: This is an open randomized multicenter pilot trial. Forty patients with EOC selected to receive NACT will be randomized 1:1 to receive daily addition of tinzaparin or no tinzaparin. The processing and treatment of the patients will otherwise follow the recommendations in the Swedish National Guidelines for Ovarian Cancer. Before every cycle of chemotherapy, preoperatively, and 3 weeks after the last cycle of chemotherapy, a panel of biomarkers, including CA-125, will be measured.Patients: Inclusion criteria are women aged 18 years or older, World Health Organization performance status 0–1, histologically confirmed high-grade serous, endometrioid or clear cell EOC, International Federation of Gynecology and Obstetrics (FIGO) stages III-IV. In addition, a CA-125 level of ≥ 250 kIE/L at diagnosis. Exclusion criteria are contraindications to LMWH, ongoing or recent treatment with unfractionated heparin, LMWH, warfarin or non-vitamin K antagonist oral anticoagulants.Interpretation: This study will make an important contribution to the knowledge of the anti-neoplastic effects of tinzaparin in EOC patients and may thus guide the planning of a future study on the impact of tinzaparin on survival in EOC.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Lindahl, GabrielDepartment of Oncology, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden
(författare)
-
Spetz Holm, Anna-ClaraDepartment of Obstetrics and Gynecology, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden
(författare)
-
Bergmark, KarinDepartment of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden
(författare)
-
Dahm Kähler, PernillaDepartment of Obstetrics and Gynecology, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden
(författare)
-
Fekete, BoglarkaDepartment of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden
(författare)
-
Ottander, UlrikaUmeå universitet,Obstetrik och gynekologi(Swepub:umu)ulaotr95
(författare)
-
Öfverman, Charlotte,1970-Umeå universitet,Institutionen för diagnostik och intervention,Onkologi(Swepub:umu)chli0003
(författare)
-
Israelsson, PernillaUmeå universitet,Institutionen för diagnostik och intervention,Onkologi(Swepub:umu)peaisn03
(författare)
-
Falknäs, LailaDepartment of Obstetrics and Gynecology, Ryhov hospital, Sweden
(författare)
-
Rosenmüller, AndersDepartment of Obstetrics and Gynecology, Västervik hospital, Sweden
(författare)
-
Tiefenthal Thrane, MalenaDepartment of Obstetrics and Gynecology, Sweden
(författare)
-
Halili, ShefqetDepartment of Obstetrics and Gynecology, Värnamo hospital, Sweden
(författare)
-
Lindahl, Tomas L.Department of Biomedical and Clinical Sciences, Division of Clinical Chemistry and Pharmacology, Linköping University, Linköping, Sweden
(författare)
-
Jenmalm, Maria C.Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden
(författare)
-
Kjølhede, PrebenDepartment of Obstetrics and Gynecology, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden
(författare)
-
Department of Obstetrics and Gynecology, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, SwedenDepartment of Oncology, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Acta Oncologica: Medical Journals Sweden63, s. 581-5850284-186X1651-226X
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Karlsson, Anna
-
Lindahl, Gabriel
-
Spetz Holm, Anna ...
-
Bergmark, Karin
-
Dahm Kähler, Per ...
-
Fekete, Boglarka
-
visa fler...
-
Ottander, Ulrika
-
Öfverman, Charlo ...
-
Israelsson, Pern ...
-
Falknäs, Laila
-
Rosenmüller, And ...
-
Tiefenthal Thran ...
-
Halili, Shefqet
-
Lindahl, Tomas L ...
-
Jenmalm, Maria C ...
-
Kjølhede, Preben
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
Acta Oncologica
- Av lärosätet
-
Umeå universitet